BioSpace News Archive

ASPIVIX SA, a developer of medical technologies to advance gynecological care, today announced positive results from its ADVANCE Women (Atraumatic Device using VAcuum Technology for CErvical Procedures in Women) study.

Oak Hill Bio (“Oak Hill”), a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced that the Company sponsored a symposium at the 10th Annual International Conference on Clinical Neonatology that took place from May 21-23, 2022 in Turin, Italy.

Terremoto Biosciences today announced it has raised $75 million in a Series A financing.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has successfully completed a capital raise to support the Company’s R&D activities and improve its financial structure.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will host a key opinion leader (KOL) webinar about TNX-201.

Jaguar Health (NASDAQ:JAGX) today announced that Napo Therapeutics, the Italian corporation established by the company in Italy in 2021 that focuses on expanding crofelemer access in Europe, has submitted an Orphan Drug Designation (ODD) application for crofelemer for a rare congenital diarrheal disorder (CDD) condition called microvillus inclusion disease (MVID) to the European Medicines Agency (EMA).

Alercell, announced today that it will begin distributing an HPV DNA based test kit: “Meltpro HPV genotype test” the test is based on DNA sequencing analysis.

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 54,246,358 shares of common stock (the “Shares”) at a purchase price of $1.46 per share, resulting in gross proceeds of $79.2 million.

ResMed announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Bernstein Strategic Decisions Conference on Wednesday, June 1, 2022, beginning at approximately 1:30 p.m. at the New York Hilton Midtown in New York City.

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that it has appointed Xavier Avat as Chief Business Officer.